Cargando…

Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer

Breast cancer is the second most common cancer among women in the United States in which the standard of care treatment is surgery with adjunctive therapy. Cryoablation, which destroys the tumor using extremely cold temperatures while preserving the potential tumor antigens, is a promising alternati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sardela de Miranda, Flávia, Castro, Maribel, Remmert, Nicole, Singh, Sharda P., Layeequr Rahman, Rakhshanda, Melkus, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582696/
https://www.ncbi.nlm.nih.gov/pubmed/37860001
http://dx.doi.org/10.3389/fimmu.2023.1258873
_version_ 1785122388814331904
author Sardela de Miranda, Flávia
Castro, Maribel
Remmert, Nicole
Singh, Sharda P.
Layeequr Rahman, Rakhshanda
Melkus, Michael W.
author_facet Sardela de Miranda, Flávia
Castro, Maribel
Remmert, Nicole
Singh, Sharda P.
Layeequr Rahman, Rakhshanda
Melkus, Michael W.
author_sort Sardela de Miranda, Flávia
collection PubMed
description Breast cancer is the second most common cancer among women in the United States in which the standard of care treatment is surgery with adjunctive therapy. Cryoablation, which destroys the tumor using extremely cold temperatures while preserving the potential tumor antigens, is a promising alternative to surgical resection. It is less invasive, cosmetically appeasing, cost-effective, and capable of contributing to the abscopal effect – the immune response targeting potential distant metastasis. However, to maximize the immunologic benefit of cryoablation in biologically high-risk breast cancers, combination with therapies that enhance immune activation, such as immune checkpoint inhibitors (ICIs) may be necessary. This mini review describes the fundamentals of cryoablation and treatment with ICIs, as well as discuss the caveats in both strategies and current clinical trials aimed to improve this approach to benefit patients.
format Online
Article
Text
id pubmed-10582696
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105826962023-10-19 Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer Sardela de Miranda, Flávia Castro, Maribel Remmert, Nicole Singh, Sharda P. Layeequr Rahman, Rakhshanda Melkus, Michael W. Front Immunol Immunology Breast cancer is the second most common cancer among women in the United States in which the standard of care treatment is surgery with adjunctive therapy. Cryoablation, which destroys the tumor using extremely cold temperatures while preserving the potential tumor antigens, is a promising alternative to surgical resection. It is less invasive, cosmetically appeasing, cost-effective, and capable of contributing to the abscopal effect – the immune response targeting potential distant metastasis. However, to maximize the immunologic benefit of cryoablation in biologically high-risk breast cancers, combination with therapies that enhance immune activation, such as immune checkpoint inhibitors (ICIs) may be necessary. This mini review describes the fundamentals of cryoablation and treatment with ICIs, as well as discuss the caveats in both strategies and current clinical trials aimed to improve this approach to benefit patients. Frontiers Media S.A. 2023-10-04 /pmc/articles/PMC10582696/ /pubmed/37860001 http://dx.doi.org/10.3389/fimmu.2023.1258873 Text en Copyright © 2023 Sardela de Miranda, Castro, Remmert, Singh, Layeequr Rahman and Melkus https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Sardela de Miranda, Flávia
Castro, Maribel
Remmert, Nicole
Singh, Sharda P.
Layeequr Rahman, Rakhshanda
Melkus, Michael W.
Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
title Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
title_full Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
title_fullStr Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
title_full_unstemmed Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
title_short Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
title_sort leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582696/
https://www.ncbi.nlm.nih.gov/pubmed/37860001
http://dx.doi.org/10.3389/fimmu.2023.1258873
work_keys_str_mv AT sardelademirandaflavia leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer
AT castromaribel leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer
AT remmertnicole leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer
AT singhshardap leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer
AT layeequrrahmanrakhshanda leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer
AT melkusmichaelw leveragingcryoablationandcheckpointinhibitorsforhighrisktriplenegativebreastcancer